We’re invested in health to develop the next generation of medical innovations.

From early-stage seed investment through to expansion capital, we support life science companies from proof-of-concept through to commercialisation.

Ground breaking medical innovation, better patient outcomes, strong financial returns.

Brandon has been effective in raising successive funds that collectively cover the spectrum of life science venture investing. We also have a co-investment arrangement with our investors, providing significant capacity to support our advancing portfolio companies.

active portfolio companies

Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom

Investment
Portfolio

Recognising the effort required to commercialise a great idea, we partner with entrepreneurs for the long-haul, working collaboratively with them to support the development and commercialisation of their technology, thereby creating value for their teams, our investors and ultimately benefiting patients.

We like to invest early - we have been the founding investor for most of our current portfolio companies

Perx

Digitally-scaled care management program that uses daily, persistent motivation for people managing any chronic conditions.
Pheon Therapeutics

Developing first-in-class ADCs to treat cancer
TamoRx

Developing novel immuno-oncology small molecule inhibitors
NRG Therapeutics

Developing disease-modifying mitochondrial therapeutics for neurodegenerative disorders
Entact Bio

Developing a new class of therapeutics that enhance the function of beneficial proteins
CatalYm

Reversing GDF-15-mediated immunosupression to induce anti-tumour responses
Myricx Bio

Developing a completely novel class of payloads for antibody drug conjugates (ADCs), based on inhibitors of the enzymes, N-myristoyltransferases (NMT) for the treatment of cancer.
Axelia Oncology

Biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response.
See our investment portfolio

News

View all posts

Contact Us

Melbourne

Level 9, 31 Queen Street

Melbourne VIC 3000

Phone +61 3 9657 0700

Email: info@brandoncapital.com.au

Sydney

Suite 2.05, 1 York Street

Sydney NSW 2000

Phone +61 2 8227 7080

Email: info@brandoncapital.com.au

San Francisco

Brandon Capital LLC

1 Letterman Ave, Suite C3-330

San Francisco, CA 94129

Phone +61 3 9657 0700

Email: info@brandoncapital.com.au

London

The Gridiron Building, 1 Pancras Square

Kings Cross, London N1C 4AG

United Kingdom

Email: info@brandoncapital.com.au

For media inquiries, contact

Kirrily Davis

kdavis@brandoncapital.com.au

+61 401 220 228


© Copyright 2024 Brandon Capital Partners

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.